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IMMUNOLOGICAL UNRESPONSIVENESS INDUCED 
BY CAPSULAR POLYSACCHARIDE OF 
CRYPTOCOCCUS NEOFORMANS
CHAPTER I 
INTRODUCTION
High levels of capsular polysaccharide of 
Crvptococcus neoformans have been demonstrated in the body 
fluids of patients with meningeal and disseminated cryptococ­
cosis (5j 7) 8, 30). The polysaccharide levels decline 
during the recovery phase of the disease, and circulating 
antibodies appear. Transitory antibody titers have been 
reported by Gordon and Vedder (I8) in some patients in early 
stages of the disease. Polysaccharide titers seem to reflect 
the severity of the disease state; the presence of anti­
bodies indicates a favorable prognosis (18). A number of 
studies have been done with polysaccharide preparations 
isolated from C. neoformans: however they have not provided 
sufficient information to determine the exact role that the 
capsular polysaccharide plays in the disease process of 
cryptococcosis.
1
2The antigenic characteristics of the capsular ma­
terial of Ç. neoformans have been studied hy various workers. 
KLigman (26) failed to induce precipitins in rabbits by in­
jecting crude capsular polysaccharide of C. neoformans. 
Neither agglutinins nor precipitins could be demonstrated in 
rabbits given purified polysaccharide, intravenously (33). 
However, in a more recent study Al-Naib (4-) has shown a 
transient agglutinin response in rabbits injectea intra- 
peritoneally with 5000 ]ig or 0.005 Pë of purified polysac­
charide. Pretreatment of rabbits with cryptococcal poly­
saccharide greatly decreased the agglutinin titers produced 
in response to formalin-killed C. neoformans cells (33). 
Unsuccessful attempts have also been made to demonstrate 
humoral antibodies in mice injected with 5, 25, or 100 jug 
of polysaccharide in complete Freund’s adjuvant (20).
When polysaccharide conjugated to bovine gamma globulin was 
used as the immunogen, agglutinins specific for the polysac­
charide could be demonstrated (19).
Further information about the antigenic nature of 
the capsular polysaccharide of C. neoformans can be obtained 
from protection studies which have been done using the poly­
saccharide or immunogens containing polysaccharide.
Gadebusch (16) showed that the subcutaneous administration 
of varying amounts of purified capsular polysaccharide, 
given 1^ days before a virulent challenge dose of C. 
neoformans. failed to protect mice. In fact, the
3polysaccharide at the highest concentrations made the animals 
more susceptible to challenge. Gadebusch therefore suggested 
that the high doses of polysaccharide had induced immuno­
logical "paralysis." Louria (28) demonstrated a similar 
effect when he immunized mice with heat killed, strongly en­
capsulated Ç. neoformans cells, and found that after lethal 
challenge, they died somewhat earlier than controls. Mice 
immunized with a weakly encapsulated strain were slightly 
protected against challenge. Abrahams and Gilleran (2) re­
ported that immunization of mice with large doses of formalin- 
killed cells (6 X 10® cells/injection) induced a "paralyzing" 
effect which they suggested to be due to an increase in 
amount of capsular material present in the vaccine.
Gadebusch (16) showed mice could be protected when injected 
with a polysaccharide-resin complex; however, Goren (19) 
failed to protect mice by immunizing with polysaccharide 
conjugated to bovine gamma globulin. Using Bordetella 
pertussis as an adjuvant with killed cryptococcal cells as a 
vaccine, Abrahams (1) demonstrated a 95 to 100^ survival rate 
in mice after challenge.
Since the demonstration of antibodies or protection 
in animals after treatment with C. neoformans capsular 
polysaccharide or polysaccharide-containing-antigens has 
been somewhat inconsistent, it seems important at this time 
to attempt to explain this variation. All of the previously 
cited results indicate that the polysaccharide is capable
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of stimulating an immunological unresponsive state when 
given in sufficient quantities and an immune state when 
given in very small quantities or with a material which 
increases its adjuvanticity. The effects that cryptococcal 
polysaccharide have on the immunological response in animals 
is reminiscent of those effects produced by pneumococcal 
polysaccharides. Felton (15) noted that mice treated with 
larger than immunizing amounts of pneumococcal polysac­
charide could not survive subsequent challenge with the 
homologous organism, and he called this phenomenon immuno­
logical paralysis. Currently, it is generally agreed that 
the terms immunological tolerance, immunological paralysis, 
immunological unresponsiveness, and antigen overloading can 
be used interchangeably, since all of these phenomena repre­
sent aspects of the same basic biological mechanisms (10,
11, 27). An operational definition of tolerance used in a 
review by Leskowitz (27) is : "tolerance represents a state
of specific immunologic nonreactivity to an antigenic 
stimulus which, in normal animals, would be followed by a 
recognizable and measurable response."
It seems to be agreed by most reviewers (11, 21,
27, 36) that the bulk of evidence supports "central" failure 
of the immunologic apparatus as the mechanism for immuno­
logical unresponsiveness. Dresser and Hitchison (11) 
explain "central" failure as an alteration of the properties 
of immunologically competent cells in such a way that a
5restricted range of reactivity is deleted. Paralysis re­
sulting from neutralization of antibody has been suggested 
from some studies using pneumococcal polysaccharide (11). 
This is the strongest evidence provided which supports a 
mechanism of paralysis other than "central" failure.
The possibility that cryptococcal polysaccharide can 
induce immunological unresponsiveness has been suggested by 
Gadebusch (16), Salvin (340, Abrahams and Gilleran (2), and 
Bennett and Hasenclever (6). Some workers have attributed 
the reduction of antibody titers (33), the failure to 
demonstrate antibodies (40), and the lack of protection (17) 
in animals after subjection to cryptococcal polysaccharide 
to be due to antibody neutralization by excess antigen.
There is a lack of understanding of how the animal's im­
munological system responds to cryptococcal polysaccharide; 
therefore the purposes of this study were to determine 
whether or not cryptococcal polysaccharide could induce 
tolerance in accordance with Leskowitz's operational def­
inition; and if so to gain further knowledge concerning the 
mechanism by which the state of immunological unresponsive­
ness was established.
CHAPTER II 
MATERIALS AND METHODS
Experimental animals. Eight to 10 week old New 
Zealand white rabbits weighing 1.2-2A  kg were used in 
studying the immunological responses to varying concentra­
tions of capsular polysaccharide.
Male arid female 6-8 week old Swiss white hybrid mice 
from a colony maintained in our laboratory were used in 
LD^q and infection studies. For hemolytic plaque studies,
10 week old male CBA/J inbred mice (Jackson Laboratory, Bar 
Harbor, Maine) were used.
Organism. Crvptococcus neoformans isolate 18^ used 
throughout this work is a weakly encapsulated form which 
was originally isolated in 1958 from lungs of a patient at 
Charity Hospital, New Orleans, Louisiana. It was obtained 
in 1961 from Dr. Lorraine Friedman and has been maintained 
in our laboratory since that time on Sabouraud’s glucose 
agar. Antiserum prepared against strain 18>+ formed 
precipitin bands on double diffusion agar plates with Type 
A polysaccharide but not with Types B or C; therefore 18^ 
was considered to be a Type A Ç, neoformans.
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7Determination of LD^q and infection of mice. The 
organism was grown in flasks of neopeptone-dextrose dialysate 
broth (12) at 30 C with constant shaking for 3 days. Hemo- 
cytometer counts were made, and appropriate suspensions were 
prepared in sterile physiological saline (SPS). Spread 
plates were made to determine the number of viable cells.
The 2k day LD^q was determined by injecting 100 mice with 
varying numbers of viable C. neoformans cells. Each mouse 
was injected with 0.1 ml of the appropriate cell concentra­
tion and the number of survival days was noted. Calculation 
of the LD^o was done according to the method of Reed and 
Muench (32).
Preparation of formalin-killed C. neoformans cells. 
After growing 48 hr at 37 0 on slants of medium prepared 
with 20 g agar, 10 g neopeptone, 10 g glucose, 2 g yeast 
extract, and 5 g NaCl in 1 1 distilled water, cells of C. 
neoformans were suspended in 0.85^ NaCl containing 2% 
formalin and were stored for 24 hr at 25 C . The cells were 
washed once in SPS and heated for 30 min at 56 C. Following 
a second washing, the cells were suspended in SPS containing
0.5^ formalin and were stored at 4 C. Before using the 
cells were washed three additional times with SPS. Cells 
prepared in this manner were used in immunization of rabbits 
and in microagglutination tests.
Isolation and purification of polysaccharide. Crude 
polysaccharide was prepared by growing C. neoformans on
8neopeptone-dextrose dialysate broth (12) at 30 C for 3 days 
and by employing the methods of Evans and Theriault (13)» 
Purification techniques of Gadebusch (16) were used. The 
dried polysaccharide was stored in a desiccator at room 
temperature. For use the appropriate quantity of polysac­
charide was dissolved in SPS and centrifuged at 27)750 x g 
for 20 min. The upper 3 A  of the solution was used in pre­
paring the desired concentrations of polysaccharide.
Preparation of nolvsaccharide-incomnlete Freund's 
adjuvant emulsion. For challenge immunization of mice an 
incomplete Fruend's adjuvant-polysaccharide emulsion was 
prepared by continuous grinding and drop-wise adding of 1 
volume of polysaccharide solution (2.5 |ig polysaccharide/ml) 
into a mortar containing 1 volume of a mixture of 5 parts 
Marcole 52 (Humble Oil and Refining Co.) and 1 part Arlacel 
A (Hill Top Research, Inc., Miamiville, Ohio). After all 
the polysaccharide had been added and the mixture appeared 
white, further émulsification was carried out by passing 
the material through an 18 gauge needle until the emulsion 
formed discrete and stable drops on the surface of water.
For challenge immunization each mouse was injected intra- 
peritoneally (ip) with 0.1 ml of the emulsion. This amount 
contained 0.125 pg of polysaccharide.
Preparation of antigen for sensitization of sheep 
red blood cells (SRBC). After growing C. neoformans 18^ in 
neopeptone dialysate broth for 3 days at 30 C, formalin was
9added to give a 2^ final concentration, and the culture was 
allowed to remain at room temperature for 18 hr. The cells 
were removed by centrifugation and the supernatant was 
brought to pH 7*0 using 0.1 N NaOH. The cell free extract 
was then dialysed against 4 changes of pH y.O saline and 
stored at -20 C until used. This antigen, referred to from 
here on as HA antigen, was used for sensitization of sheep 
erythrocytes as well as a skin test antigen.
Sensitization of SBBC. Two tenths ml of washed, 
packed SRBC was suspended in 10 ml of phosphate buffered 
saline pH y.2 (PBS), and 0.2 ml of HA antigen was added to 
the cell suspension. The mixture was incubated at 37 C for 
h5 min, then the sensitized cells (SRBC-HA) were washed 3 
times in PBS. Sheep erythrocytes sensitized in this manner 
were used in microhemagglutination tests, microhemolysis 
tests, and hemolytic plaque assays.
Preparation of antiserum. Five New Zealand white 
rabbits were hyperimmunized by giving each rabbit intra-
o
venously (iv) 1 ml containing 5 x 10 formalin-killed 
cryptococcal cells every other day for a total of 7 injec­
tions. After 7 days the rabbits were given another series 
of 7 injections of formalin-killed cells. Bleeding was done 
from the central ear artery 7 days after the last injection. 
Sera were collected and stored at -20 C in 1 ml volumes 
until used. All 5 rabbits were skin tested with 0.1 ml of 
HA antigen the day after they were bled.
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Serological procedures.
1. Agar gel double diffusion plate. The agar gel 
diffusion methods of Ouchterlony as modified by Heiner (22) 
were employed. Instead of ordinary agar, purified agar 
(Difco) was used. Capsular polysaccharide at a concentra­
tion of 5000 |ig/ml was placed in the center well, and six 
test sera were put into the surrounding wells. A positive 
control serum was included each time the test was run. All 
rabbit serum samples collected were checked for precipitins 
in this manner.
2. Microagglutination test. The Microtiter tech­
nique using lucite V-shaped bottom Microtiter plates (Cooke 
Engineering Co.) was employed for determining agglutinin 
titers in rabbit and mouse sera. For titrating rabbit serum
0.85^ NaCl was used as the diluent, and for mouse serum PBS 
was used as the diluting fluid. All solutions used in Micro- 
titre tests were made with distilled, deionized water. The 
microagglutination test was performed by making serial two­
fold dilutions of serum so that each well in the Microtiter 
plate contained 0.025 ml of diluted serum. To each serum 
dilution was added 0.025 ml of a suspension of washed 
formalin-killed C. neoformans cells which had been diluted 
to give 60^ transmission using 1/2" x tubes in a 
Spectronic "20" (Bausch and Lomb) spectrophotometer set at 
500 mp. The Microtiter plates were sealed and incubated
for 2.5 hr about 18" from a desk lamp before being read for
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agglutination. The highest dilution of serum in which there 
was not a smooth white button of cells in the well apex was 
taken as the titer.
3* Microhemagglutination test. For the micro­
hemagglutination test to detect antibodies against C. 
neoformans. disposable, non-flexible, "V" shaped bottom 
Microtiter plates were used. Serum was diluted as for micro­
agglutination tests; however the diluent was ^% normal rabbit 
serum in saline in this procedure. All test sera and serum 
used in the diluent had been heat inactivated at 56 C for 
30 min and had been adsorbed with 0.15 ml of packed SRBC per 
ml of serum for 30 min at room temperature. To each serum 
dilution was added 0.025 ml of a 0.5# suspension of SRBC-HA 
made up in normal rabbit serum in saline. Plates were 
sealed and incubated in a 37 0 incubator for 1 hr, followed 
by 18 hr at ^ C. The titer was considered to be the highest 
serum dilution in which there was not a smooth button formed 
in the well apex. Each time microhemagglutination tests were 
run a diluent control, a normal serum control, and a positive 
serum control were included.
4. Microhemolysis test. This test was employed to 
see if SRBC-HA would lyse in the presence of specific anti­
serum and complement, for this is a prerequisite for using 
the sensitized cells in the hemolytic plaque technique.
Heat inactivated, SRBC adsorbed serum was diluted in two­
fold manner in veronal buffered saline pH 7.5 (VBS) in
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Microtiter, "U" shaped bottom, disposable, non-flexible 
plates. To the serim dilutions was added 0.025 ml of 0.5^ 
suspension of SRBC-HA in VBS. After the plates had incu­
bated at 37 C for 1 hr, 0.025 ml of a 1:10 dilution of 
guinea pig complement in VBS was added to each well. The 
plates were gently shaken to make sure all cells were re­
suspended and then incubated an additional hour at 37 C with 
occasional shaking during the first 30 min of this incuba­
tion period. After an overnight storage at 4 C, the plates 
were read. The microhemolysis titer was the highest serum 
dilution in which there was hemolysis. The following con­
trols were run:
VBS + SRBC-HA + Complement
Test Serum + SRBC-HA + VBS
Normal Serum + SRBC-HA + Complement
Positive Serum + SRBC-HA 4 Complement
To determine whether or not a serum sample was anti- 
complementary, the serum was added to a SRBC-hemolysis 
system before the final incubation with complement. If 
hemolysis was inhibited by the serum then it was considered 
to be anti-complementary.
5. Adsorption and inhibition procedures. To de­
termine if the microhemagglutination and the microhemolysis 
tests were specific for antibodies against cryptococcal 
antigens the following procedures were employed:
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a. Adsorption of antiserum with formalin-killed 
C. neoformans cells. To 0.2 ml of thrice washed, packed 
Ç. neoformans cells was added 1 ml of titered test antiserum. 
After thorough mixing the suspension was incubated at room 
temperature for 30 min, then centrifuged, and the serum was 
collected. The adsorbed serum was retitered by the micro­
hemagglutination and microhemolysis techniques.
b. Inhibition of hemagglutination and hemolysis 
with purified polysaccharide. The antiserum was diluted as 
for microhemagglutination or microhemolysis tests; however 
before the addition of SRBC-HA, 0.025 ml of 200 )xg/ml con­
centration of polysaccharide was added to each well. The 
plates were incubated for 1 hr at 37 C before the remainder 
of the respective test was performed.
Hemolytic plaque technique. The procedure used to 
detect and enumerate plaque forming cells in the mouse spleen 
which were specific for cryptococcal antigen was primarily 
that of Jerne, Nordin, and Henry (25). Spleen cell suspen­
sions were made by pressing the freshly excised spleen 
through a stainless steel fine mesh sieve with 5 ml of cold 
Spinner base Minimal Eagle’s Medium (MEM) (Schwarz Bio- 
Research, Orangeburg, N.Y.). Five-tenths ml of the spleen 
cell suspension and 0.1 ml of a 20^ suspension of SRBC-HA 
were added to 2 ml of 0.75^ agar in MEM containing 1 mg of 
diethylaminoethyl dextran (DEAE dextran) (Pharmacia,
Uppsala, Sweden). The suspension was mixed and poured onto
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a layer of 10 ml of 1.4^ agar in MEM containing 1 mg/ml of 
DEAE dextran. After 15 min at room temperature the plates 
were incubated at 37 C for 1'hr. One and one half ml of a 
1:5 dilution of guinea pig complement in veronal buffered 
saline was added to each plate, and the plates were again 
incubated at 37 C for 30 min. After 2 hr at room tempera­
ture the excess complement was removed from the plates, and 
they were refrigerated at 4 0 overnight. Each plate was 
covered with 3 ml of a hemoglobin stain made by mixing 10 ml 
of 2% benzidine solution in glacial acetic acid with 0.5 ml 
of 30^ HgOg and 90 ml of distilled water. When the plate 
had turned blue the stain was decanted, and the plaques were 
enumerated under a stereoscope using the 0.75 X ocular.
Three plates were done per spleen.
Experimental design. To determine what effects C. 
neoformans polysaccharide had on the immunological response 
in animals, all the animal studies were designed to ini­
tially treat the animals with varying concentrations of 
polysaccharide, followed l4 days later by challenging the 
immunological capacity of the animals. The challenge was 
by one of the following: formalin-killed C. neoformans
cells, viable C. neoformans cells, or polysaccharide in 
incomplete Freund's adjuvant.
1. Immunological unresponsiveness in rabbits. 
Twenty-one rabbits were divided into 7 groups of 3 rabbits 
per group, so that the mean body weight of each group was
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1.7 ± 0.1 kg. On day 0 each group of animals was given a 
different concentration of purified polysaccharide or saline 
ip, and 14- days later all rabbits were challenge immunized 
with a series of 7 iv injections, each of 6 x 10*^  formalin- 
killed cells, given every other day for 1^ days. Seven days 
after the last challenge immunizing injection all rabbits 
were bled from the central ear artery, and sera were titered 
by means of the microagglutination test. Table 1 shows the 
treatment schedule in detail.
2. Immunological unresponsiveness in mice.
a. Challenge with viable C. neoformans cells. 
Sixty, 6-8 week old female Swiss white mice were used in this 
study. For each concentration of polysaccharide or saline,
10 mice were used. The polysaccharide or saline was given
ip on day 0. All mice were challenged on day l4 with 1 LD^q 
of C. neoformans. iv. The number of days each animal sui'- 
vived after challenge was noted, and the mean life expectancy 
was determined by summing all survival days of all mice in 
the group and dividing by the number of mice in that group. 
The statistical test employed to determine if there was a 
significant difference in the mean life expectancies of test 
animals and controls was Student's t test. Polysaccharide 
concentrations used and further details are listed in 
Table 2.
b. Challenge with polysaccharide in incomplete 
Freund's adjuvant. In this study 90, ten week old, CBA/J
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Table 1 .— Schediile for polysaccharide treatment and challenge
immunization of rabbits
Weight
of
rabbit
(kg)
Group 
averag 
we ight 
(kg)
Polysac­
charide 
given ip 
(;ig/ml )
Challenge Immunization
Group 
No.
No. cells 
given iv
Days
given*
1
1.3 
1 .8 
2.5 1.8
Saline 6 X 10?
1h,16,l8, 
20,22,24, 
and 26
2
1.3 
1 .6 
2.h 1 .7
0.005 6 X 10?
14,16,18, 
20,22,24, 
and 26
3
1.5
1.7
2.1 1 .7
0.05 6 X 10?
14,16,18, 
20,22,24, 
and 26
If
1.5
1.7
1.9 1.7
5.0 6 X 10?
14,16,18, 
20,22,24, 
and 26
5
1.5
1.6 
2.0 1.7
500 6 X 10?
14,16,18, 
20,22,24, 
and 26
6
1.5
1.5 
2.3 1.8
5,000 6 X 10?
14,16,18,
20,22,24,
and 26
7
1 .6 
1.6 
1.8 1.7
50,000^ 6 X 10^
14,16,18, 
20,22,24, 
and 2d
^Indicates day relative to injection of polysac­
charide on day 0.
^This amount of polysaccharide was contained in 5 nil.
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Table 2.— Schedule for 
of mice
polysaccharide 
with viable C .
treatment
neoformans
and challenge
Number 
of mice 
per. 
group
Polysac­
charide 
given ip 
Cjig/0.1 ml )
Challenge Immunization
Group
No.
No', viable 
cells, iv
! Day
giveur
10 10 500 1.9 X 10^ l4
12 10 5 1.9 X 10^ 1^ -
1^ 10 0.05 1.9 X 10^ 1^
16 10 0.0005 1.9 X 10^ 1^
18 10 0.00005 1.9 X 10^ 1^-
20 10 saline 1.9 X 105 1^-
^Indicates day relative to injection of polysac­
charide on day 0.
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male mice were used. The mice were divided into 5 of
j.v
10 mice each. On day 0 the animals in each group were
jected ip with one of the following concentrations of ‘iWy-
saccharide: 500 /ig, 50 fig, 5 Jig? 0.5 Mg or saline. Dl^ '’^^ yss|il lays
*+, 7j and 1^ -, three mice from each group were bled by^
sanguination. On day 14 all remaining mice in each gr^ ^^
were injected ip with 0.1 m3, of polysaccharide in
Freund's adjuvant. Then three mice from each group we/ bled
on days 10, 21, and 20. Hemolytic plaque assays were^^^'a *oso(?iie on
the spleens of each animal bled on days *+, 10, 21, and
This complete experiment was repeated on 90 more CBA/J!  ^^ 0
week old male mice, to give a total of 6 mice per
tion group per bleeding time. Table 3 shows in detail
treatment and bleeding schedules.
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Table 3*— Schedule for polysaccharide treatment, bleeding,
tion of mice
Polysac­
charide 
given ip
Xjig/0.1ml)
No. of mice 
bled for 
serum titra­
tion
Polysac­
charide in 
ICpa ip 
(jig/0.1ml)
No. of mice 
bled for 
serum titra­
tion
Day 0 Ifb 7 1^ 18^ 21^ 28^
500 3 3 3 0.125 3 3 3
50 3 3 3 0.125 3 3 3
5 3 3 3 0.125 3 3 3
0.5 3 3 3 0.125 3 3 3
saline 3 3 3 0.125 3 3 3
&ICF = Incomplete Freund's Adjuvant
hemolytic plaque assay were done on all mice bled 
on these days.
CHAPTER III 
RESULTS AND DISCUSSION
Evaluation of serological tests and antigen speci­
ficity. To use the hemolytic plaque assay technique to de­
tect and enumerate plaque forming spleen cells which were 
producing antibodies specific for C. neoformans. a sensi­
tizing antigen had to be produced and a method for coating 
sheep erythrocytes with the cryptococeal antigen had to be 
developed. After finding a good sensitizing antigen and de­
vising a method for tagging the SRBC, it was then necessary 
to find serological procedures whereby one could test, (1) 
the efficiency of the sensitization process, (2) the speci­
ficity of the tagged cells, and (3) the ability of the 
sensitized cells to lyse in the presence of specific antiserum 
and complement.
Five rabbits were used to produce high titer crypto- 
coccal antiserum for testing of the sensitized erythrocytes. 
Preliminary testing of sensitivity and specificity of the 
SRBC-HA for the cryptococcal system was done with rabbit 
anti-cryptococcal serum. Larger quantities of serum could 
be obtained from these animals, thereby making possible
20
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repeated testing of the same sample. The hemagglutination 
and hemolysis tests were also performed on mouse serum with 
similar results as with rabbit serum; however titers were 
lower in mouse sera, and after adsorbing the sera with SRBC, 
the titers were always reduced 1 to 3 tubes. Table 4 shows 
a comparison of titers determined by using the microag­
glutination test, the microhemagglutination test, the micro­
hemolysis test with sera not adsorbed with SRBC, and the 
microhemolysis test with sera adsorbed with SRBC, plus 
precipitin results from double diffusion plates. In all 
cases the hemagglutination titers were lower than the ag­
glutination titers which indicated that the hemagglutination 
test was not as sensitive as was the agglutination test for 
rabbit anti-cryptococcal antibodies. The hemagglutination 
test did not appear to be less sensitive than the agglutina­
tion test in the mouse system; however due to an insufficient 
amount of mouse antiserum this could not be verified through 
repeated testing of the same serum sample.
In three of the five rabbits the hemolysis titers 
were higher than either the agglutination or the hemag­
glutination titers. This increase of titer was probably not 
due to the hemolysis test being more sensitive but rather 
that the hemolysis test demonstrated a different population 
of antibodies than did the agglutination or hemagglutination 
test. This conclusion was drawn because different immuno­
globulin classes can be distinguished, in many instances, by
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Table 4-.— Comparison of results from various serological
test procedures
Logg titer and (Reciprocal of titer)
Rabbit
No.
Agglut­
ination
Hemagglut
ination
Hemolysis 
- Serum non 
adsorbed
Hemolysis
Serum
adsorbed^
Precip­
itin
1286 5 (32) 4 (16) 8 (256) 8 (256) Negb
1296 9 (512) 8 (256) 7 (128) 7 (128) Neg
1571 7 (128) 5 (32) 8 (256) 8 (256) Pos^
1517 0 (Neg) 7 (128) 3 (8) Neg
2394 5 (32) 4(16) 5 (32) 0 (Neg) Neg
NR8Ü 0 (Neg) 0 (Neg) 0 (Neg) 0 (Neg) Neg
^Serum was adsorbed with SRBC 
^Neg = negative
cpos = positive with 2 precipitin bands 
‘^NRS = normal rabbit serum
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function, for example IgM readily fixes complement and has a 
high cytolytic or hemolytic efficiency while the other 
classes fix complement less readily and are wèalaLy or not at 
all cytolytic (31).
By comparing the hemolysis titers before and after 
adsorption with sheep red blood cells, a determination could 
be made of how antibodies against SRBC effected the hemolysis 
titer results. If the anti-cryptococcal titer was high 
enough to mask the titer to sheep erythrocytes, then there 
was no change in titer after adsorption; however if the anti- 
cryptococcal titer was low then it was mask by anti-SRBC 
antibodies. Therefore adsorption of the serum was necessary 
to get an accurate anti-cryptococcal titer.
To confirm that the hemolysis and hemagglutination 
tests using the erythrocytes coated with HA antigen were 
specific for C, neoformans, two more tests were done. For 
the first, the antiserum was adsorbed with formal in-killed 
Ç. neoformans cells, then retitered by the two test systems. 
The results are shown in Table 5. In all but one case, the 
titers were negative after adsorption with C. neoformans 
cells. The second test was an inhibition procedure whereby 
capsular polysaccharide was allowed to incubate with anti­
serum dilutions before the sensitized erythrocytes were 
added. The polysaccharide completely blocked the hemag­
glutination or the hemolysis in each case (Table 5). If the 
hemolysis or hemagglutination had been due to some
2k
Table 5»— Anti-cryptococcal titers before and after adsorp­
tion with C. neoformans cells and inhibition with 
polysaccharide
Serological
test
Rabbit No.
1286 1296 1571 1517 2394
Hemaggluti­
nation
Untreated
k (16)* 8 (256) 5 (32) 4 (16)
Adsorbed
serumb 0 (Neg)C 0 (Neg) 0 (Neg) 0 (Neg)
Poly.
treated^ 0 (Neg) 0 (Neg) 0 (Neg) 0 (Neg)
Hemolysis
Untreated
serum 8 (256) 7 (128) 8 (256) 3 (8) 0 (Neg)
Adsorbed
serumb 3 (8) 0 (Neg) 0 (Neg) 0 (Neg) 0 (Neg)
Poly.
treated^ 0 (Neg) 0 (Neg) 0 (Neg) 0 (Neg) 0 (Neg)
^Log2 titer (Reciprocal of titer)
^Serum was adsorbed with Ç. neoformans cells 
°Neg = Negative
^Serum was treated with 200 p.g of polysaccharide
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antigen-antibody system other than cryptococcal, then 
neither the adsorption nor the inhibition procedures would 
have changed the titers of the antisera. The HA antigen was 
considered specific for C. neoformans antibodies.
To determine the effectiveness of the HA antigen for 
detecting delayed hypersensitivity (cell-bound antibody), 
the 5 hyperimmunized rabbits, 10 normal rabbits, and 10 
guinea pigs which had histoplasmin positive skin tests were 
skin tested with HA antigen. The results are shown in 
Table 6. Only the 2 rabbits with the highest hemolysis 
titers (1/256) gave positive skin reactions. All normal 
rabbits and all histoplasmin positive guinea pigs were 
negative with HA antigen. From the very limited testing 
done in this study there is some evidence that the HA antigen 
might prove to be an effective skin testing antigen. There 
was no cross reactivity with Histoplasma infected animals, 
and untreated animals were uniformly negative. Whether the 
HA antigen was detecting all sensitized animals can not be 
answered from this study. Further work is necessary before 
an accurate evaluation can be made on the effectiveness of 
HA antigen as a skin testing agent.
Effects of cryptococcal polysaccharide on the immuno­
logical responsiveness of rabbits. Rabbits were injected, 
ip, with various concentrations of cryptococcal polysac­
charide and l!+ days later given a challenge immunization 
series of formalin-killed C. neoformans cells. Seven days
26
Table 6.— Delayed skin reactivity in rabbits using HA 
antigen as the skin testing material
Rabbit No.
2h hr Induration 
(mm)
2k- hr Erythema 
( mm)
1286 10 X 10 15 X 18
1296 Negative 5 x 5
1571 13 X 10 18 X 13
1517 Negative Negative
239^ Negative 1 2 x 1 2
Normal®’ Negative Negative
&Ten normal rabbits showed the same results
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after the challenge immunization series, the animals were 
bled and agglutination titers were determined. The results 
of this experiment are shown in Figure 1. The rabbits 
treated initially with 50,000 jag of polysaccharide showed 
essentially no response to the challenge immunization 
(reciprocal titer of 1.26). Normal rabbit sera gave re­
ciprocal titers of 1 to 2. Animals initially treated with 
saline (controls) responded to the challenge immunization 
with an average reciprocal titer of 12.6. These results ful­
filled Leskowitz's definition of tolerance, for the group of 
animals given 50,000 pg of polysaccharide showed "a specific 
non-reactivity to the antigenic stimulus (challenge immuni­
zation) which in normal animals, would be followed by a 
recognizable and measurable response (reciprocal titer of 
12.6).” If the lack of a significant titer in the group re­
ceiving 50,000 ;og of polysaccharide had been due to a simple 
neutralization of antibodies by excess polysaccharide rather 
than immunological tolerance, then the curve of Figure 1 
would not have been as it is but rather would have appeared 
as a line of continuous descent from 12.6, the reciprocal 
titer of the control animals, to the point 1.26, the recip­
rocal titer of the animals treated with the highest concentra­
tion of polysaccharide. The fact that the animals initially 
treated with 500 pg showed an enhanced immunological response 
to challenge immunization (reciprocal titer of 16) also was 
evidence against simple antibody neutralization. The
28
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Figure 1. Effects of cryptococcal polysaccharide 
concentration (mpg) on agglutinin titers in rabbits after 
challenge immunization. Dashed line represents average 
titer of controls.
29
boosted agglutinin response indicated that 500 jag was an 
immunizing dose of cryptococcal polysaccharide.
The challenge immunization protocol for the rabbits 
consisted of 7 injections of 6 x 1 0 ^  cryptococcal cells ex­
tended over a IM- day period and introduced a mosaic of anti­
gens. For a more accurate determination of immunizing and 
paralyzing doses of polysaccharide, a challenge immuniza­
tion procedure using a single injection containing only a 
small quantity of polysaccharide would have been much 
better.
Effects of pretreatment with polysaccharide on the 
mean life expectancy in mice challenged with C. neoformans. 
Mice, given various concentrations of polysaccharide ranging 
from 0,00005 pig to 500 pg, were challenged 14 days later 
with 1 LD^o of 0. neoformans. The mean life expectancy (MLE) 
for each concentration group was determined and compared to 
MLE of the control (saline treated) group using Student's t 
test. The only group which showed a significant difference 
from controls was that group treated with 5 pg of polysac­
charide (Figure 2). The MLE of that group was greater than 
the controls which indicated some protection stimulated by 
the 5 pg of polysaccharide. These results indicated that the 
immunizing dose for cryptococcal polysaccharide was similar 
to that found for pneumococcal and Klebsiella polysac­
charides, Howard (23) reported 0,5 and 5 Mg of pneumococcal 
Type III polysaccharide to be immunizing doses and 500 pg to
32.
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Figure 2. Effects of cryptococcal polysaccharide 
concentrations (in#ig) on mean life expectancy (MLE) in mice 
after challenge with 1 LD^q of C. neoformans, Dashed line 
represents K,E of controls.
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be a paralyzing dose in CBA mice. Wu and Tice (^1) showed 
that 5 fig of Klebsiella polysaccharide would immunize mice, 
while 1000 *ig paralyzed them. A 0.5 P-g concentration of 
cryptococcal polysaccharide was not used in this experiment; 
however it was in a later study and did prove to be an im­
munizing dose in mice (Figure 5). Whether or not 500 pg of 
cryptococcal polysaccharide was a paralyzing dose for mice 
could not be determined from the MLE study. The animals in 
that group died at the same rate as those in the control 
group. One would expect animals treated with 500 pg of 
polysaccharide to die faster because their immunological 
responses had been paralyzed by the polysaccharide. The in­
crease in death rate was not observed in this study possibly 
because the challenge dose of Orvutococcus was so great that 
the ability of an animal to produce antibodies was of no 
significance.
The extremely small doses of polysaccharide were 
used to demonstrate "low dose" paralysis with this antigen; 
however if "low dose" paralysis was produced, it was not 
demonstrated for the same reason as for "high dose" paraly­
sis. Low-zone tolerance was first described by Mitchison 
(29) using bovine serum albumin. This phenomenon has not 
been reported with polysaccharides; however Siskind and 
Howard (35) tried without success to elicit a "low dose" zone 
of paralysis with pneumococcal polysaccharide.
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Effects of treatment with polysaccharide on the 
number of plaque forming cells In mouse spleens and ag­
glutinin titers before and after challenge Immunization.
This study was designed to determine whether or not antibody- 
producing cells were present in mouse spleens after the 
animals had been subjected to immunizing and paralyzing 
doses of cryptococcal polysaccharide. In addition, it was 
to demonstrate how the antibody-producing cell populations 
compared with antibody titers.
Responses of CBA/J mice injected, ip, with saline,
0 .5, 5) 50, or 500 |ig of cryptococcal polysaccharide were 
evaluated by means of hemolytic plaque assay technique using 
polysaccharide coated sheep erythrocytes and by means of ag­
glutination tests. Four days following polysaccharide in­
jection the number of plaque forming cells in the mouse 
spleens were determined, and sera were assayed for aggluti­
nins. The results from the hemolytic plaque assays are in 
Figure 3* Agglutinin results are in Figure k. Each point 
on the two graphs was an average of the results from 6 mice.
Animals treated with saline (controls) had 36 plaque 
forming cells (RFC) per spleen. Aisenberg and Wilkes (3) 
reported a background range of ^0 to 60 RFC per normal CBA 
mouse spleen. Agglutinin titers of normal mouse sera or 
saline treated mouse sera were found to average 1/2.1 to
1/3.1.
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Figure 3- Effects of cryptococcal polysaccharide 
concentration (mug) on numbers of plaque forming cells (PFC) 
in the mouse spleen, k- days after polysaccharide injection. 
Area in dashed lines represents background levels of PFC in 
normal CBA mice.
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Figure Effects of cryptococcal polysaccharide 
concentration (mjig) on agglutinin titers ^ days after poly­
saccharide injection. Area in dashed lines represents titer 
levels of normal CBA mice.
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Specific antibody-forming cells were demonstrated in 
all animals treated with polysaccharide. The greater num­
bers of PFC were found in the groups treated with 5? 50, and 
500 |ig of polysaccharide as compared to the 0.5 pg group. 
However, the average agglutinin titers peaked in the group 
receiving 0.5 Pg of polysaccharide and showed a continuous 
reduction with increasing concentration groups (Figure k).
The highest concentration group (500 pg) had an average titer 
which was not above background. They therefore were con­
sidered as negative.
To explain these results two assumptions were made: 
(1) that the antibody produced to one injection of polysac­
charide was primarily macroglobulin and (2) that antibody 
titers rose in parallel with the number of antibody-producing 
cells. The former assumption was supported by the work of 
Al-Naib (^) and the fact that IgM Is considered to be the 
first antibody to appear after antigen stimulation (1*i, 31)» 
The latter assumption was supported by the findings that in 
the SRBC antigen-antibody system the number of PFC paral­
leled the 19s antibody titers (24, 25)» Upon the basis of 
the two assumptions, the antibody titers in the 5, 50, and 
500 pg groups should have greatly exceeded the titer of the
0.5 pg group, because the former groups had many more PFC 
in their spleens than did the 0.5 /ig group. However this 
was not the case. The gradual decrease in timers with in­
creasing concentration groups was probably due to
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neutralization of antibody, the greatest number of antibodies 
being neutralized by 500 ;ig, less neutralized with 50 jag, and 
still less with 5 jig-
Agglutinin titers also were determined at 7 and 14- 
days after polysaccharide treatment. These results appear 
in Figure 5- The agglutinin titers peaked at k days in the 
0-5 jig group and at 7 days in all other concentration 
groups, then the titers fell rapidly during the following 9 
and 7 days, respectively. The rise and fall in titers shown 
in each concentration group followed the form of a typical 
primary immunological response.
The next study was designed to investigate what 
effect challenge immunization would have on agglutinin titers 
and the numbers of PFC in animals which had been given saline 
or one of the h concentrations of polysaccharide. The chal­
lenge immunization (c.i.) of 0.125 jag of cryptococcal poly­
saccharide in incomplete Freund’s adjuvant was given 14- days 
after initial polysaccharide treatment. This time interval 
was chosen because Brooke (9) showed that an induction 
period was required for the production of tolerance to 
pneumococcal polysaccharide. Hemolytic plaque assays and 
agglutinin titers were determined 4- and 7 days following 
challenge immunization.
Four days following challenge immunization, the 
numbers of PFC were greatest in the 0.5 jag group, followed 
by the controls (Figure 6). Animals treated with 5 jag had
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Polysaccharide treatment, 
on day 0:
Saline
0.) tig
500 tig
9
DAYS
Figure 5* Agglutinin titers in mice treated with 
various concentrations of cryptococcal polysaccharide on day 
0. t indicates challenge.immunization with 0,125 P-S poly­
saccharide in incomplete Freund's adjuvant.
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Figure 6. Average numbers of plaque forming cells 
(PFC) ^ days after challenge immunization in the spleens of 
animals previously treated with various concentrations of 
polysaccharide (mjig). Dashed lines enclose background PFC 
count in normal CBA mice. A  represents controls.
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fewer PFC than did the control group. The number of PFC 
found in the group treated with 50 p.g of polysaccharide was 
just above background which indicated only a slight re­
sponse to challenge immunization. Animals treated with 
500 pLg of polysaccharide were unable to respond to the chal­
lenge immunization; thus demonstrating they were tolerant. 
Agglutinin titers were positive in all groups except the 
500 Jig treated one. The agglutination results are shown in 
Figure 5*
By 7 days after challenge immunization the number of 
PFC had dropped in all groups (Figure 7)* However by Ik- days 
after c.i., the numbers of PFC were increasing in the groups 
initially treated with 50 and 500 p.g of polysaccharide.
There was still a trend of decrease in PFC in the other 3 
groups (Figure 7)* The increase in PFC in the two high con­
centration groups can be explained better after the following 
discussion.
The data shown in Figure 7 indicated that all the 
doses of polysaccharide stimulated a production of specific 
antibody forming cells. A similar response to pneumococcal 
Type III polysaccharide has been noted independently in 
Sterzl's laboratory (38) and by Howard (23). By means of 
the hemolytic plaque technique using polysaccharide coated 
mouse erythrocytes, it was demonstrated in Sterzl’s labora­
tory that the antibody-forming cells were present at 6 days 
after polysaccharide injection and disappeared subsequently
40
Polysaccharide treatment, 
oh (%y 0;
▼  Saline
0.5 jUg
5 Mg 
50 Mg 
500 Më
U 200
12 f  16 
DAYS
Figure 7. Average numbers of plaque forming cells 
(PFC) in CBA mice treated with various concentrations of 
polysaccharide on day 0. ♦ indicates challenge immunization
with 0.125 Mg polysaccharide in incomplete Freund's adjuvant.
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as the state of paralysis was established. Howard using the 
Biozzi rosette technique noted an increase in rosette-forming 
cells after treatment with paralyzing doses of polysac­
charide but no decrease over a period of 28 days.
After challenge immunization it was apparent that 
500 }ig was a paralyzing dose, and partial paralysis was in­
duced with 5 and 50 p.g. Five-tenth jig was considered an 
immunizing dose.
According to the "Unitarian concept" of immunocompe­
tent cell differentiation, if all stages of differentiation 
of immunocompetent cells occur in the presence of antigen 
then proliferation is restricted (37, 38, 39). When large 
concentrations of cryptococcal polysaccharide were injected 
subcutaneously, the polysaccharide could be detected in all 
reticulo-endothelial tissue 4 weeks later (16). Therefore 
when a paralyzing dose of cryptococcal polysaccharide was 
given, all susceptible immunocompetent cells were activated 
and differentiated without proliferation into antibody- 
forming cells. This group of cells was presumably what the 
k day hemolytic plaque assay was demonstrating. Sterzl (38) 
reported that antibody-producing cells have a half-life of 
2-3 days. Considering this half-life and since the antibody- 
forming cells did not proliferate, the challenge immunization 
stimulated only a small number of immunocompetent cells. The 
results of the hemolytic plaque assays on days 18 and 21 re­
flected that very few immunocompetent cells differentiated
If2
into antibody-forming cells in animals treated with ^0 and 
500 |ig of polysaccharide. By day 28 the amount of polysac­
charide remaining in the animal was probably in the im­
munizing dose range; therefore as new immunocompetent cells 
were produced they were stimulated to differentiate and 
proliferate. This would account for the increase in anti­
body forming cells noted at 28 days in the 50 and 500 pg 
groups.
CHAPT.B IV 
SUMMARY AND CONCLUSIONS
An antigen isolated from the culture filtrate of C. 
neoformans was effective in coating SRBC which could subse­
quently be used to detect specific anti-cryptococcal anti­
bodies in microhemagglutination, microhemolysis, and 
hemolytic plaque assay techniques. The antigen also proved 
to be a potentially valuable skin testing antigen for 
cryptococcosis.
Immunological unresponsiveness was demonstrated in 
rabbits treated with 50,000 jag of cryptococcal polysaccharide. 
Five hundred jag appeared to be an immunizing dose, for rab­
bits given this dosage responded to challenge immunization 
with higher agglutinin titers than did animal injected with 
saline.
In mice, paralysis could be induced with 500 jag of 
C. neoformans polysaccharide, and an immune response could 
be elicited with 0.5 or 5 jag. Prior to establishment of 
paralysis there was a transient phase of increased numbers 
of antibody-forming cells in the spleen; however the antibody
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produced by the cells could not be detected in the serum, 
presumably due to neutralization by excess antigen. Follow­
ing induction of tolerance, challenge immunization did not 
elicit an increase in antibody-forming cells. This indicated 
a "central" failure of the immune mechanism. Spontaneous 
recovery from paralysis was suggested because there was an 
increase in antibody-forming cells 28 days after injection 
of the paralyzing dose of polysaccharide.
The results of this study indicate that in crypto­
coccosis, the circulating polysaccharide serves two functions: 
first, it neutralizes antibody produced during the tolerance 
induction period, and secondly it stimulates all susceptible 
immunocompetent cells to differentiate without proliferation. 
As long as polysaccharide levels remain sufficiently high in 
the body fluids of the patient, both activities are taking 
place. When polysaccharide levels are reduced, for example 
after treatment with amphotericin B, then the patient slowly 
gains control of the disease as the immunocompetent cells 
are replenished.
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